Intellia Therapeutics, a biotech company focusing on CRISPR-based therapies for rare diseases and oncology, recently disclosed a significant insider sale by its president and CEO, John M. Leonard. The sale involved 34,146 shares, totaling $314,484.66, as reported in a SEC Form 4 filing on Jan. 5.
John M. Leonard’s transaction history indicates a consistent pattern of similar-sized sales in the past, suggesting no significant change in selling behavior. The recent sale reduced his direct stake in Intellia to 1,013,339 shares, while his indirect ownership remained unaffected at 58,415 shares held by a trust entity.
Despite the insider sale, Intellia Therapeutics continues to advance its genome editing therapeutics pipeline, targeting rare diseases and oncology. With a focus on CRISPR/Cas9 technology and strategic collaborations with pharmaceutical partners, the company remains well-positioned to address unmet medical needs in genetic, oncological, and autoimmune conditions.
